Secondary Parkinson Disease (Secondary Parkinsonism)

Subscribe to Selected New Research on Secondary Parkinson Disease

32 relevant articles (0 outcomes, 5 trials/studies) found for this Disease

Description: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)

Also Known As:

Secondary Parkinsonism; Parkinson Disease, Secondary; Parkinson Disease, Secondary Vascular; Parkinson Disease, Symptomatic; Parkinsonism, Secondary; Parkinsonism, Symptomatic; Secondary Vascular Parkinson Disease; Parkinsonism, Atherosclerotic; Symptomatic Parkinsonism; Atherosclerotic Parkinsonism; Symptomatic Parkinson Disease

Disease Context: Research Results

Nervous System Diseases: 3406

Central Nervous System Diseases: 929

Movement Disorders: 1472

Parkinsonian Disorders: 4707

Secondary Parkinson Disease: 32

MPTP Poisoning: 109

Postencephalitic Parkinson Disease: 27

Brain Diseases: 1117

Basal Ganglia Diseases: 181

Parkinsonian Disorders: 4707

Secondary Parkinson Disease: 32

MPTP Poisoning: 109

Postencephalitic Parkinson Disease: 27

Related Diseases

1.	Parkinson Disease (Parkinson's Disease)
2.	Intracranial Arteriosclerosis (Cerebral Atherosclerosis)
3.	Parkinsonian Disorders (Parkinsonism)
4.	Encephalitis (Encephalitis, Rasmussen)
5.	Stroke (Strokes)
18 Diseases and 13 more articles analyzed in the Research Interface, order at left...

Experts

1.	Formichi, Patrizia: 1 article (04/2008)
2.	Radi, Elena: 1 article (04/2008)
3.	Battisti, Carla: 1 article (04/2008)
4.	Federico, Antonio: 1 article (04/2008)
5.	Clay, Patrick G: 1 article (02/2003)
6.	Adams, Molly M: 1 article (02/2003)
7.	Ling, Monica J: 1 article (03/2002)
8.	Aggarwal, Arun: 1 article (03/2002)
9.	Morris, John G L: 1 article (03/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Secondary Parkinson Disease:

1.	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 01/01/1993 - "In this debate, while MPTP has proven to be a most amenable model for the study of secondary parkinsonism it has not resolved the dilemma; equally uncertain are the claims derived from the MPTP hypothesis of nigral vulnerability that selective MAO inhibition has a protective effect on the natural history of Parkinson's disease" 08/01/1998 - "From observations in brain of patients with secondary parkinsonism, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine parkinsonism in the rhesus monkey, as well as the regional DA transporter distribution in the primate substantia nigra, it is concluded that PD may be caused by any exogenous and/or endogenous toxin using the transporter system for DA and to some degree the other brain monoamines (noradrenaline, serotonin), to enter, and damage, the respective monoamine neurons" Get all the results and reference details, order at left...
2.	Antipsychotic Agents (Antipsychotics)IBA 12/01/2005 - "OBJECTIVE: In the current study, the role of the glabelar sign was evaluated as a clinical component of the secondary parkinsonism induced by neuroleptics" 12/01/2005 - "CONCLUSIONS: These results suggested that glabelar sign measures a condition different from secondary parkinsonism induced by neuroleptics" 12/01/2005 - "RESULTS: One hundred three patients having secondary parkinsonism induced by neuroleptics were evaluated" 12/01/2005 - "MATERIALS AND METHODS: Patients with psychosis having secondary parkinsonism induced by neuroleptics were evaluated with the Simpson-Angus Rating Scale for extrapyramidal side effects" 01/01/2007 - "METHOD: The relevant literature was retrieved via Medline (1960-2005), using combinations of the (mesh) terms 'antipsychotic agents', 'dystonia', 'parkinson disease', 'secondary', 'dyskinesias', 'drug-induced', 'asphyxia' and the key words 'dysphagia' en 'respiratory'" Get all the results and reference details, order at left...
3.	alpha-SynucleinIBA 04/15/2008 - "In this study we evaluated the apoptotic response to oxidative stress induced by 2-deoxy-d-ribose (dRib) in peripheral blood lymphocytes (PBLs) of two siblings with Parkinson disease secondary to A53T alpha-synuclein mutation" 04/15/2008 - "Oxidative-stress-induced apoptosis in PBLs of two patients with Parkinson disease secondary to alpha-synuclein mutation." Get all the results and reference details, order at left...
4.	Monoamine Oxidase (MAO)IBA 01/01/1993 - "In this debate, while MPTP has proven to be a most amenable model for the study of secondary parkinsonism it has not resolved the dilemma; equally uncertain are the claims derived from the MPTP hypothesis of nigral vulnerability that selective MAO inhibition has a protective effect on the natural history of Parkinson's disease" Get all the results and reference details, order at left...
5.	Histamine (Histamine Dihydrochloride)IBA 01/01/1975 - "The authors conducted a study of the histamine system (H), diaminoxidase (DO), histaminopexic index (HPI) using the biological method in 127 patients with hypertensive disease and cerebral atherosclerosis with brain circulation disturbances and in 23 patients with atherosclerotic parkinsonism" Get all the results and reference details, order at left...
6.	Direction compoundIBA 09/01/1999 - "Using anatomic studies of the direction of nerve fibers around the substantia nigra, we attempted to depict this entity with multishot diffusion-weighted MR imaging to evaluate its topographic changes in patients with Parkinson's disease and secondary parkinsonism" Get all the results and reference details, order at left...
7.	Levodopa (L Dopa)FDA LinkGeneric 01/01/1984 - "Based on the established electrophoretic mobility of L-DOPA and on pathogenetic assumptions, the authors carried out multiple modality treatment employing transcerebral L-DOPA electrophoresis in 48 patients with postencephalic and atherosclerotic parkinsonism" 01/01/2001 - "To investigate the significance of vascular lesions as a cause of secondary parkinsonism, we analyzed the symptomatic characteristics, the width of the substantia nigra pars compacta (SNpc) on MRI and the responsiveness to L-dopa in 227 parkinsonian cases, excluding those with drug-induced parkinsonism and neurodegenerative diseases other than idiopathic Parkinson's disease (IPD)" 10/01/1985 - "A more important different behaviour between primary and secondary parkinsonism concerns a possible reduction of VEP delay related to L-DOPA/carbidopa treatment" 10/01/1985 - "Influence of L-DOPA/carbidopa on pattern reversal VEP: behavioural difference in primary and secondary parkinsonism." 01/01/1987 - "Three cases are presented with symptomatic parkinsonism after carbon monoxide exposure, who have been treated with bromocriptine (in one case in combination with levodopa)" Get all the results and reference details, order at left...
8.	Sertraline (Zoloft)FDA LinkGeneric 11/01/1998 - "Reversible parkinsonism secondary to the use of sertraline]" 12/08/1995 - "Parkinsonism secondary to the use of sertraline]" Get all the results and reference details, order at left...
9.	Meperidine (Pethidine)FDA LinkGeneric 02/02/1984 - "Chronic parkinsonism secondary to intranasal administration of a product of meperidine-analogue synthesis." 12/01/1979 - "Chronic Parkinsonism secondary to intravenous injection of meperidine analogues." Get all the results and reference details, order at left...
10.	Dihydroxyphenylalanine (Dopa)IBA 03/01/2002 - "Dopa-responsive parkinsonism secondary to right temporal lobe haemorrahage." 08/01/2005 - "The ICD-9 CM code for paralysis agitans (332.0) did not distinguish between probable Parkinson's disease and other causes of parkinsonism, whereas the ICD-9 CM code for degenerative basal ganglia disorder (333.0) predicted having secondary parkinsonism (odds ratio [OR] = 5.0) as well as dopa-responsiveness in patients without secondary parkinsonism (OR = 4.5)" Get all the results and reference details, order at left...
37 Drugs and Important Bio-Agents and 31 more articles analyzed in the Research Interface, order at left...

Therapies and Procedures

1.	Bone Marrow Transplantation (Transplantation, Bone Marrow) 06/01/1995 - "Encephalopathy, leukoencephalopathy, and secondary parkinsonism occurred in 3 children with refractory leukemia undergoing allogenic bone marrow transplantation (BMT) who were treated with high-dose amphotericin B for pulmonary aspergillosis or sinus aspergillosis that did not involve the nervous system" Get all the results and reference details, order at left...
2.	Prostatectomy (Retropubic Prostatectomy) 05/01/2007 - "METHODS AND PROCEDURES: To report the clinical course of five patients who had had symptomatic parkinsonism developed shortly after surgery (lumbar laminectomy, prostatectomy and cholestectomy)" Get all the results and reference details, order at left...
3.	Laminectomy 05/01/2007 - "METHODS AND PROCEDURES: To report the clinical course of five patients who had had symptomatic parkinsonism developed shortly after surgery (lumbar laminectomy, prostatectomy and cholestectomy)" Get all the results and reference details, order at left...
3 Therapies and Procedures and 2 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>